{"id":12887,"date":"2019-03-20T09:03:29","date_gmt":"2019-03-20T13:03:29","guid":{"rendered":"https:\/\/medicarereport.org\/?p=12887"},"modified":"2019-03-20T09:03:29","modified_gmt":"2019-03-20T13:03:29","slug":"biosimilar-approval-and-adoption-in-the-u-s-needs-to-be-expedited","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=12887","title":{"rendered":"Biosimilar approval and adoption in the U.S. needs to be expedited"},"content":{"rendered":"<p>(By Carlos Sattler and Sheila Frame for ST<em>A<\/em>T)<\/p>\n<p><span class=\"big-cap-wrap\"><span class=\"big-cap\">G<\/span><\/span>eneric versions of brand-name small-molecule drugs saved Americans\u00a0<a href=\"https:\/\/www.gao.gov\/assets\/590\/588064.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">more than $1 trillion<\/a>\u00a0between 1999 and 2010. Biosimilars now have the potential to create substantial savings on complex biologic drugs, but only if we can remove the unnecessary barriers that stall their approval and adoption.\u00a0 Continue reading <a href=\"https:\/\/www.statnews.com\/2019\/03\/20\/biosimilar-approval-adoption-expedite\/\">article here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre>Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Carlos Sattler and Sheila Frame for STAT) Generic versions of brand-name small-molecule drugs saved Americans\u00a0more than $1 trillion\u00a0between 1999<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17,31,21,15],"tags":[],"class_list":["post-12887","post","type-post","status-publish","format-standard","hentry","category-emerging-health-issues","category-fda","category-health-care-finance","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12887"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12887\/revisions"}],"predecessor-version":[{"id":12888,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12887\/revisions\/12888"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}